
KIM FOREST — Investor Relations & Filings
Kim Forest Enterprise Co., Ltd. specializes in precision medicine and molecular diagnostics, providing integrated solutions for clinical research and healthcare. The company offers a "One Stop Solution" encompassing experimental consultation, laboratory equipment supply, and bioinformatics analysis. Key products and services include Next-Generation Sequencing (NGS), PCR systems, ELISA readers, and high-content imaging systems. The company focuses on genetic testing for cancer screening, hereditary diseases, and personalized health management. By synthesizing genomic data with clinical insights, Kim Forest facilitates biomarker identification and the development of optimized treatment strategies. Its portfolio also extends to customized enzymes, drug screening technologies, and precision nutrition, supporting the advancement of personalized medicine through comprehensive technical expertise and reliable diagnostic reporting.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 115年第1季財務報告書 — 202601_6645_AI1.pdf | 2026-05-11 | Chinese | |
| 115年04月內部人持股異動(事後) | 2026-05-05 | Chinese | |
| 115年04月董事會成員及持股 | 2026-05-05 | Chinese | |
| 公告本公司115年第一季財務報告董事會 預計召開日期為115年05月08日 | 2026-04-30 | Chinese | |
| 114年第4季財務報告書 — 202504_6645_AIC.pdf | 2026-04-21 | Chinese | |
| 114年第4季財務報告書 — 202504_6645_AIA.pdf | 2026-04-21 | Chinese |
Browse filings by year
1 year| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 45580484 | 115年第1季財務報告書 — 202601_6645_AI1.pdf | 2026-05-11 | Chinese | ||
| 41459706 | 115年04月內部人持股異動(事後) | 2026-05-05 | Chinese | ||
| 41457341 | 115年04月董事會成員及持股 | 2026-05-05 | Chinese | ||
| 39887117 | 公告本公司115年第一季財務報告董事會 預計召開日期為115年05月08日 | 2026-04-30 | Chinese | ||
| 34695803 | 114年第4季財務報告書 — 202504_6645_AIC.pdf | 2026-04-21 | Chinese | ||
| 34695802 | 114年第4季財務報告書 — 202504_6645_AIA.pdf | 2026-04-21 | Chinese | ||
| 34695801 | 114年第4季財務報告書 — 202504_6645_AI3.pdf | 2026-04-21 | Chinese | ||
| 34695800 | 114年第4季財務報告書 — 202504_6645_AI1.pdf | 2026-04-21 | Chinese | ||
| 34695799 | 114年第4季財務報告書 — 202503_6645_AI1.pdf | 2026-04-21 | Chinese | ||
| 34695798 | 114年第4季財務報告書 — 202502_6645_AI1.pdf | 2026-04-21 | Chinese | ||
| 34695797 | 114年第4季財務報告書 — 202501_6645_AI1.pdf | 2026-04-21 | Chinese | ||
| 34690456 | 114年年報及股東會資料 — 2026_6645_20260522F17.pdf | 2026-04-20 | Chinese | ||
| 34690455 | 114年年報及股東會資料 — 2025_6645_20260522FE4.pdf | 2026-04-20 | English | ||
| 34690454 | 114年年報及股東會資料 — 2025_6645_20260522F04.pdf | 2026-04-20 | Chinese | ||
| 34690442 | 114年年報及股東會資料 — 2026_6645_20260522F02.pdf | 2026-04-20 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
GI Innovation Inc.
Researches and develops protein-based drugs for immuno-onco…
|
358570 | KR | Professional, scientific and te… |
|
Ginkgo Bioworks Holdings, Inc.
Operates a horizontal platform for cell programming and syn…
|
DNA | US | Professional, scientific and te… |
|
GRAIL, Inc.
A healthcare company developing blood tests for multi-cance…
|
GRAL | US | Professional, scientific and te… |
|
GT Biopharma, Inc.
Clinical-stage immuno-oncology company developing therapies…
|
GTBP | US | Professional, scientific and te… |
|
Guard Therapeutics International AB
Clinical-stage biotech developing therapies to prevent acut…
|
GUARD | SE | Professional, scientific and te… |
|
Gubra A/S
Biotech and CRO focused on peptide drugs for metabolic and …
|
GUBRA | DK | Professional, scientific and te… |
|
HALOZYME THERAPEUTICS, INC.
Biopharmaceutical firm licensing technology to convert IV d…
|
HALO | US | Professional, scientific and te… |
|
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.
Provides integrated R&D and manufacturing services for chem…
|
301096 | CN | Professional, scientific and te… |
|
Hangzhou Tigermed Consulting Co., Ltd.
Leading global Contract Research Organization (CRO) for ful…
|
3347 | HK | Professional, scientific and te… |
|
Hangzhou Tigermed Consulting Co.,Ltd.
Provides clinical research solutions for pharmaceutical, bi…
|
300347 | CN | Professional, scientific and te… |
KIM FOREST via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/52599/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=52599 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=52599 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=52599 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 52599}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for KIM FOREST (id: 52599)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.